Gilead Sciences, Inc. (NASDAQ:GILD) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 19,599,824 shares, a decline of 18.9% from the October 13th total of 24,156,580 shares. Based on an average trading volume of 10,442,870 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.5% of the shares of the company are short sold.

Gilead Sciences (NASDAQ:GILD) opened at $73.77 on Friday. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a current ratio of 3.68, a quick ratio of 4.74 and a debt-to-equity ratio of 1.10. The stock has a market capitalization of $95,383.76, a PE ratio of 7.62, a P/E/G ratio of -1.22 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the company earned $2.75 EPS. Gilead Sciences’s revenue was down 13.2% on a year-over-year basis. analysts forecast that Gilead Sciences will post 8.53 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.82%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total value of $5,509,508.29. Following the completion of the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the completion of the transaction, the executive vice president now directly owns 113,237 shares of the company’s stock, valued at $8,945,723. The disclosure for this sale can be found here. Insiders sold 446,819 shares of company stock valued at $36,269,486 over the last three months. 1.30% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of the business. Ropes Wealth Advisors LLC raised its position in Gilead Sciences by 7.4% in the 3rd quarter. Ropes Wealth Advisors LLC now owns 16,633 shares of the biopharmaceutical company’s stock valued at $1,348,000 after purchasing an additional 1,150 shares in the last quarter. Zeke Capital Advisors LLC raised its position in Gilead Sciences by 159.4% in the 3rd quarter. Zeke Capital Advisors LLC now owns 23,972 shares of the biopharmaceutical company’s stock valued at $1,942,000 after purchasing an additional 14,730 shares in the last quarter. Amalgamated Bank raised its position in Gilead Sciences by 2.0% in the 3rd quarter. Amalgamated Bank now owns 154,871 shares of the biopharmaceutical company’s stock valued at $12,548,000 after purchasing an additional 3,084 shares in the last quarter. Auxier Asset Management raised its position in Gilead Sciences by 20.0% in the 3rd quarter. Auxier Asset Management now owns 8,130 shares of the biopharmaceutical company’s stock valued at $659,000 after purchasing an additional 1,357 shares in the last quarter. Finally, Twin Capital Management Inc. raised its position in Gilead Sciences by 33.8% in the 3rd quarter. Twin Capital Management Inc. now owns 96,830 shares of the biopharmaceutical company’s stock valued at $7,845,000 after purchasing an additional 24,470 shares in the last quarter. 74.38% of the stock is currently owned by institutional investors.

Several research analysts have recently weighed in on GILD shares. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a research note on Thursday, August 31st. Deutsche Bank AG reaffirmed a “buy” rating and set a $81.00 target price on shares of Gilead Sciences in a research note on Thursday, August 31st. Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price for the company in a research note on Friday, October 13th. Credit Suisse Group reaffirmed an “outperform” rating and set a $85.00 target price (up from $79.00) on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $85.92.

TRADEMARK VIOLATION NOTICE: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/gilead-sciences-inc-gild-short-interest-down-18-9-in-october/1696865.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.